Home >
Access the latest news, business developments, company updates, industry trends, events and more.
Greenfield BioVentures is an investment company focused on early-stage science in the biopharmaceuticals space. Its preferred investments are typically in pre-clinical stages of experimentation and in...
In the latest sign that the major biopharma players are eagerly joining the big tech rush on the gene therapy market, Pfizer has snagged an...
GestVision reports researchers have demonstrated that CRD (Congo Red Dot) urine diagnostic test results strongly correlate with a diagnosis of preeclampsia. “This is an important...
Biohaven Pharmaceutical Holding Company has purchased an FDA Priority Review Voucher to use with the NDA submission of rimegepant Zydis® ODT in the second quarter of 2019 …...
Cybrexa Therapeutics reports that the FDA- and EMA-approved poly ADP-ribose polymerase (PARP) inhibitor rucaparib (marketed as Rubraca®) is conjugated in lead candidate CBX-11 (alphalex™-rucaparib). The...
Farmington-based immunotherapy startup CaroGen reports it has won a $1.4 million grant from the National Institutes of Health to accelerate development of its lead drug candidate, a potential...
Innovation to Impact at Yale announces a small grant competition for promising innovators committed to addressing substance abuse and addiction. Innovators will apply for one...
New Haven biotech Arvinas reports it has begun its first human trial on a groundbreaking drug that aims to fight prostate cancer by inducing the body...
Vishwas Paralkar, PhD, Chief Scientific Officer of Cybrexa, will present the first set of preclinical data supporting its alphalex™-PARP inhibitor lead candidate, CBX-11, at the upcoming...
InveniAI® Corporation was featured in a Microsoft-sponsored series that showcases companies making a transformative impact in their industry with AI technology. Krishnan Nandabalan, Ph.D., President...